NCT04720768View on ClinicalTrials.gov

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions
MelanomaMetastasis
Interventions
DRUG

Binimetinib

MEK inhibitor

DRUG

Encorafenib

BRAF inhibitor

DRUG

Palbociclib

CDK4/6 inhibitor

Trial Locations (4)

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3004

RECRUITING

Alfred Health, Melbourne

3084

RECRUITING

Austin Hospital, Heidelberg

3128

RECRUITING

Box Hill Hospital, Box Hill

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER